A Ludwig Cancer Research study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive ...

APL is, therefore, a unique subtype of acute myeloid leukemia potentially curable with targeted therapies without any exposure to conventional DNA-damaging chemotherapy. Cure rates of APL can be ...

RAPID-CRISPR test quickly and accurately diagnoses acute promyelocytic leukemia, a rare and aggressive blood cancer, with ...

In an attempt to delineate genes associated with malignant transformation in human hypergranular APL (that is, AML FAB M3), we compared gene expression profiles of APL cells and their normal ...

Expert Rev Hematol. 2012;5(4):395-407. AML: Acute myeloid leukemia; APL: Acute promyelocytic leukemia; CBF: Core-binding factor; CEBPA-DM: CCAAT enhancer-binding protein-α with double mutation ...

Revenue surged to $18.80 million in FY 2024, compared to $5.02 million in FY 2023 – an increase of 274.86% due to the consolidation of AML and APL for the full 2024 fiscal year, which contributed ...

oral-ATO is available for research and clinical use on APL patients in Singapore, Malaysia and Taiwan. The UK AML Research Network and the University of Cardiff, U.K., in collaboration with the ...

Mouse CD8, T-reg niche, T-reg activation and dendritic cells. Human PBMCs, mucosal associated invariant T cells, AML (acute myelogenous leukemia), APL (acute promyelocytic leukemia), and myeloma cells ...

Total Revenues: $26.94 million in FY 2024, up from $12.75 million in FY 2023 – an increase of 111.24% due to the consolidation of Alchemy Markets Ltd. (AML) and Alchemy Prime Ltd. (APL ...